Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives.
- The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives.
- Im proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022, said CEO, Josh Bartch.
- Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure.
- Mydecine Innovations Group's vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients.